Administrateur / Actionnariat PDMR
SMITH & NEVEU PLC
13 Mars 2024
NOTIFICATION ET DIVULGATION PUBLIQUE CONFORMÉMENT AUX EXIGENCES DE LA RÉGLEMENTATION DES ABUS DE MARCHÉ DE L'UE DES TRANSACTIONS PAR DES PERSONNES DÉCHARGEANT DES RESPONSABILITÉS DE DIRECTION (« PDMR ») ET DES PERSONNES ÉTROITEMENT ASSOCIÉES À CELLES-CI.
1. VESTING OF SHARE AWARDS UNDER THE GLOBAL SHARE PLAN 2020
On 13 March 2024, the Company received notification of the following transactions in US$0.20 ordinary shares (the "Shares") in Smith & Nephew plc (the "Company") following the vesting of awards under the Smith & Nephew Global Share Plan 2020.
i. VESTING OF 2021 PERFORMANCE SHARE PROGRAMME AWARDS MADE UNDER THE SMITH & NEPHEW GLOBAL SHARE PLAN 2020:
The awards were granted under the Global Share Plan 2020 on 21 May 2021, and vested on 11 March 2024 at 21% of target for those employees who were members of the Company's Executive Committee when the award was granted and at 33.58% for all other senior employees who received an award. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards. The number of Shares acquired includes the dividend equivalent Shares which participants receive on vested Shares. The table below sets out the number of shares under award which vested. The remaining shares under award have lapsed.
Ce qui suit concerne les personnes incluses dans la notification ci-dessous :
Motif de la notification | |
Notification initiale/Modification | Notification initiale |
Coordonnées de l'émetteur, du participant au marché des quotas d'émission, de la plate-forme d'enchères, du commissaire-priseur ou du contrôleur des enchères | |
Nom | Smith & Nephew plc |
LEI | 213800ZTMDN8S67S1H61 |
Détails de la (des) transaction (s): section à répéter pour (i) chaque type d'instrument; (ii) chaque type de transaction; (iii) chaque date; et (iv) chaque lieu où des transactions ont été effectuées | |
Description de l'instrument financier, type d'instrument
| Actions ordinaires de Smith & Nephew plc de 0.20 USD chacune
|
Code d'identification | ISIN : GB0009223206 |
Nature de la transaction | Vesting of Smith & Nephew Global Share Plan 2020: Performance Share Programme awards granted on 21 May 2021, and subsequent sale of shares to cover tax liability |
Date de l'opération | 2024 - 03 - 11 (vesting) and 2024 - 03 - 12 (market sale) |
Lieu de la transaction | Bourse de Londres (XLON) |
Nom (Positionner) |
Statut | Prix (£) | Volume | Informations agrégées |
Hélène Barraclough1 (Directeur Juridique Groupe et Secrétaire Général) | PDMR | 11.079467 | 2,443 (of which 1,154 were sold and 1,289 retained.) | N/A Transaction unique |
Bradley Canon2 (President, Orthopaedics & Americas) | PDMR | 11.079467 | 12,852 (of which 4,416 were sold and 8,436 retained.) | N/A Transaction unique |
Phil Cowdy2 (Chef du développement corporatif et des affaires corporatives) | PDMR | 11.079467 | 5,736 (of which 2,707 were sold and 3,029 retained.) | N/A Transaction unique |
Craig Gaffin1 Président, Orthopédie mondiale | PDMR | 11.079467 | 2,067 (of which 616 were sold and 1,451 retained.) | N/A Transaction unique |
Elga Löhler2 (Directeur RH) | PDMR | 11.079467 | 7,308 (of which 2,891 were sold and 4,417 retained.) | N/A Transaction unique |
Vasant Padmanabhan2 (Président Recherche & Développement ENT) | PDMR | 11.079467 | 7,161 (of which 2,875 were sold and 4,286 retained.) | N/A Transaction unique |
Scott Schaffner1 (Président Médecine du Sport) | PDMR | 11.079467 | 3,733 (of which 1,112 were sold and 2,621 retained.) | N/A Transaction unique |
1Award vested at 33.58%
2Award vested at 21.00%
All figures in these columns are stated to 6 decimal places where applicable.
ii. FINAL VESTING OF 2021 EQUITY INCENTIVE PROGRAMME AWARDS MADE UNDER THE GLOBAL SHARE PLAN 2020:
The awards were granted under the Global Share Plan 2020 on 9 March 2021. One third of the Shares vested on 9 March 2022, a further third vested on 9 March 2023 and the final third vested on 11 March 2024. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards. The number of Shares acquired includes the dividend equivalent Shares which participants receive on vested Shares.
Ce qui suit concerne les personnes incluses dans la notification ci-dessous :
Motif de la notification | |
Notification initiale/Modification | Notification initiale |
Coordonnées de l'émetteur, du participant au marché des quotas d'émission, de la plate-forme d'enchères, du commissaire-priseur ou du contrôleur des enchères | |
Nom | Smith & Nephew plc |
LEI | 213800ZTMDN8S67S1H61 |
Détails de la (des) transaction (s): section à répéter pour (i) chaque type d'instrument; (ii) chaque type de transaction; (iii) chaque date; et (iv) chaque lieu où des transactions ont été effectuées | |
Description de l'instrument financier, type d'instrument
| Actions ordinaires de Smith & Nephew plc de 0.20 USD chacune
|
Code d'identification | ISIN : GB0009223206 |
Nature de la transaction | Final vesting on 11 March 2024 of Equity Incentive Programme awards granted on 9 March 2021 under the Smith & Nephew Global Share Plan 2020, and subsequent sale of shares to cover tax liability |
Date de l'opération | 2024 - 03 - 11 (vesting) and 2024 - 03 - 12 (market sale) |
Lieu de la transaction | Bourse de Londres (XLON) |
Nom (Positionner) |
Statut | Prix (£) | Volume | Informations agrégées |
Hélène Barraclough (Directeur Juridique Groupe et Secrétaire Général) | PDMR | 11.079467 | 3,105 (of which 1,465 were sold and 1,640 retained.) | N/A Transaction unique |
Bradley Canon (President, Orthopaedics & Americas) | PDMR | 11.079467 | 7,082 (of which 2,432 were sold and 4,650 retained.) | N/A Transaction unique |
Phil Cowdy (Chef du développement corporatif et des affaires corporatives) | PDMR | 11.079467 | 5,679 (of which 2,679 were sold and 3,000 retained.) | N/A Transaction unique |
Elga Löhler (Directeur RH) | PDMR | 11.079467 | 6,328 (of which 2,502 were sold and 3,826 retained.) | N/A Transaction unique |
Vasant Padmanabhan (Président Recherche & Développement ENT) | PDMR | 11.079467 | 5,246 (of which 2,106 were sold and 3,140 retained.) | N/A Transaction unique |
Scott Schaffner (Président Médecine du Sport) | PDMR | 11.079467 | 3,562 (of which 1,060 were sold and 2,502 retained.) | N/A Transaction unique |
All figures in these columns are stated to 6 decimal places where applicable.
iii. PARTIAL VESTING OF 2022 DEFERRED BONUS SHARE AWARDS MADE UNDER THE GLOBAL SHARE PLAN 2020:
The awards were granted under the Global Share Plan 2020 on 9 March 2022. One third of the Shares vested on 9 March 2023, a further third vested on 11 March 2024 and the final third will vest on 10 March 2025. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards. The number of Shares acquired includes the dividend equivalent Shares which participants receive on vested Shares.
Ce qui suit concerne les personnes incluses dans la notification ci-dessous :
Motif de la notification | |
Notification initiale/Modification | Notification initiale |
Coordonnées de l'émetteur, du participant au marché des quotas d'émission, de la plate-forme d'enchères, du commissaire-priseur ou du contrôleur des enchères | |
Nom | Smith & Nephew plc |
LEI | 213800ZTMDN8S67S1H61 |
Détails de la (des) transaction (s): section à répéter pour (i) chaque type d'instrument; (ii) chaque type de transaction; (iii) chaque date; et (iv) chaque lieu où des transactions ont été effectuées | |
Description de l'instrument financier, type d'instrument
| Actions ordinaires de Smith & Nephew plc de 0.20 USD chacune
|
Code d'identification | ISIN : GB0009223206 |
Nature de la transaction | Partial vesting on 11 March 2024 of Deferred Bonus Share awards, granted on 9 March 2022 under the Smith & Nephew Global Share Plan 2020, and subsequent sale of shares to cover tax liability |
Date de l'opération | 2024 - 03 - 11 (vesting) and 2024 - 03 - 12 (market sale) |
Lieu de la transaction | Bourse de Londres (XLON) |
Nom (Positionner) |
Statut | Prix (£) | Volume | Informations agrégées |
Hélène Barraclough (Directeur Juridique Groupe et Secrétaire Général) | PDMR | 11.079467 | 1,769 (of which 834 were sold and 935 retained.) | N/A Transaction unique |
Bradley Canon (President, Orthopaedics & Americas) | PDMR | 11.079467 | 6,418 (of which 2,205 were sold and 4,213 retained.) | N/A Transaction unique |
Phil Cowdy (Chef du développement corporatif et des affaires corporatives) | PDMR | 11.079467 | 2,900 (of which 1,368 were sold and 1,532 retained.) | N/A Transaction unique |
Craig Gaffin Président, Orthopédie mondiale | PDMR | 11.079467 | 873 (of which 260 were sold and 613 retained.) | N/A Transaction unique |
Mizanu Kebede (Directeur Qualité & Affaires Réglementaires) | PDMR | 11.079467 | 734 (of which 273 were sold and 461 retained.) | N/A Transaction unique |
Elga Löhler (Directeur RH) | PDMR | 11.079467 | 4,139 (of which 1,637 were sold and 2,502 retained.) | N/A Transaction unique |
Vasant Padmanabhan (Président Recherche & Développement ENT) | PDMR | 11.079467 | 3,348 (of which 1,344 were sold and 2,004 retained.) | N/A Transaction unique |
Scott Schaffner (Président Médecine du Sport) | PDMR | 11.079467 | 2,433 (of which 724 were sold and 1,709 retained.) | N/A Transaction unique |
All figures in these columns are stated to 6 decimal places where applicable.
iv. PARTIAL VESTING OF 2023 DEFERRED BONUS SHARE AWARDS MADE UNDER THE GLOBAL SHARE PLAN 2020:
The awards were granted under the Global Share Plan 2020 on 9 March 2023. One third of the Shares vested on 11 March 2024, a further third will vest on 10 March 2025 and the final third will vest on 9 March 2026. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards. The number of Shares acquired includes the dividend equivalent Shares which participants receive on vested Shares.
Ce qui suit concerne les personnes incluses dans la notification ci-dessous :
Motif de la notification | |
Notification initiale/Modification | Notification initiale |
Coordonnées de l'émetteur, du participant au marché des quotas d'émission, de la plate-forme d'enchères, du commissaire-priseur ou du contrôleur des enchères | |
Nom | Smith & Nephew plc |
LEI | 213800ZTMDN8S67S1H61 |
Détails de la (des) transaction (s): section à répéter pour (i) chaque type d'instrument; (ii) chaque type de transaction; (iii) chaque date; et (iv) chaque lieu où des transactions ont été effectuées | |
Description de l'instrument financier, type d'instrument
| Actions ordinaires de Smith & Nephew plc de 0.20 USD chacune
|
Code d'identification | ISIN : GB0009223206 |
Nature de la transaction | Partial vesting on 11 March 2024 of Deferred Bonus Share awards, granted on 9 March 2023 under the Smith & Nephew Global Share Plan 2020, and subsequent sale of shares to cover tax liability |
Date de l'opération | 2024 - 03 - 11 (vesting) and 2024 - 03 - 12 (market sale) |
Lieu de la transaction | Bourse de Londres (XLON) |
Nom (Positionner) |
Statut | Prix (£) | Volume | Informations agrégées |
Hélène Barraclough (Directeur Juridique Groupe et Secrétaire Général) | PDMR | 11.079467 | 1,714 (of which 809 were sold and 905 retained.) | N/A Transaction unique |
Bradley Canon (President, Orthopaedics & Americas) | PDMR | 11.079467 | 2,818 (of which 968 were sold and 1,850 retained.) | N/A Transaction unique |
Paul Connoly (Président, Opérations mondiales) | PDMR | 11.079467 | 1,943 (of which 662 were sold and 1,281 retained.) | N/A Transaction unique |
Phil Cowdy (Chef du développement corporatif et des affaires corporatives) | PDMR | 11.079467 | 1,847 (of which 871 were sold and 976 retained.) | N/A Transaction unique |
Craig Gaffin Président, Orthopédie mondiale | PDMR | 11.079467 | 574 (of which 171 were sold and 403 retained.) | N/A Transaction unique |
Mizanu Kebede (Directeur Qualité & Affaires Réglementaires) | PDMR | 11.079467 | 1,987 (of which 738 were sold and 1,249 retained.) | N/A Transaction unique |
Elga Löhler (Directeur RH) | PDMR | 11.079467 | 2,907 (of which 1,149 were sold and 1,758 retained.) | N/A Transaction unique |
Vasant Padmanabhan (Président Recherche & Développement ENT) | PDMR | 11.079467 | 2,365 (of which 949 were sold and 1,416 retained.) | N/A Transaction unique |
Alison Parkes (Directeur de la conformité) | PDMR | 11.079467 | 1,028 (of which 486 were sold and 542 retained.) | N/A Transaction unique |
Scott Schaffner (Président Médecine du Sport) | PDMR | 11.079467 | 949 (of which 283 were sold and 666 retained.) | N/A Transaction unique |
All figures in these columns are stated to 6 decimal places where applicable.
Sarah Carné
Secrétaire général adjoint
Smith & Nephew plc
Tél : +44 (0)1923 477100
RNS peut utiliser votre adresse IP pour confirmer le respect des termes et conditions, pour analyser votre interaction avec les informations contenues dans cette communication et pour partager cette analyse de manière anonyme avec d'autres dans le cadre de nos services commerciaux. Pour plus d'informations sur la manière dont RNS et la Bourse de Londres utilisent les données personnelles que vous nous fournissez, veuillez consulter notre Politique de confidentialité.